Conus toxins: Targets and properties

IDrugs

Volumn 7, Issue 11, 2004, Pages 1011-1016

  Heading, Christine E ^a  

^a OPEN UNIVERSITY   (United Kingdom)

Author keywords

Conopeptide; Conus toxins; Drug development; Target

Indexed keywords

ACV 1; AM 336; CALCIUM CHANNEL BLOCKING AGENT; CGX 1160; CONANTOKIN G; CONOPRESSIN DERIVATIVE; CONORFAMIDE; CONOTOXIN; CONTRYPHAN DERIVATIVE; CONTULAKIN; CONTULAKIN G; G PROTEIN COUPLED RECEPTOR; ION CHANNEL; NEUROPROTECTIVE AGENT; NEUROTENSIN RECEPTOR AGONIST; NICOTINIC RECEPTOR BLOCKING AGENT; NORADRENALIN TRANSPORTER; OMEGA CONOTOXIN; OMEGA CONOTOXIN CVID; OMEGA CONOTOXIN MVIIA; OPIATE AGONIST; PROTEIN INHIBITOR; RHO CONOTOXIN; SNAIL VENOM; UNCLASSIFIED DRUG; XEN 2174;

BINDING SITE; CENTRAL NERVOUS SYSTEM; CHANNEL GATING; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; LIGAND BINDING; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NONHUMAN; ORTHOSTATIC HYPOTENSION; PERIPHERAL NERVOUS SYSTEM; RECEPTOR BINDING; REVIEW; SNAIL;

ANIMALS; CARRIER PROTEINS; DRUG DELIVERY SYSTEMS; HUMANS; ION CHANNELS; MOLLUSK VENOMS; RECEPTORS, G-PROTEIN-COUPLED; TERMINOLOGY;

EID: 9944260795     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Olivera BM: E.E. Just lecture, 1996. Conus venom peptides, receptor and ion channel targets and drug design: 50 million years of neuropharmacology. Mol Biol Cell (1997) 8 (11 ):2101-2109.
2. Terlau H, Olivera BM: Conus venoms: A rich source of novel ion channel-targeted peptides. Physiol Rev (2004) 84 (1):41-68.
3. Tsetlin VI, Hucho F: Snake and snail toxins acting on nicotinic acetylcholine receptors: Fundamental aspects and medical applications. FEBS Lett (2004) 557(1-3):9-13.
4. Mcintosh JM, Santos AD, Olivera BM: Conus peptides targeted to specific nicotinic acetylcholine receptor subtypes. Annu Rev Biochem (1999) 68:59-88.
5. Livett BG, Gayler KR, Khalil Z: Drugs from the sea: Conopeptides as potential therapeutics. Curr Med Chem (2004) 11:1715-1723.
6. Heading CE: Conus peptides and neuroprotection. Curr Opin Invest Drugs (2002) 3 (6):915-920.
7. Elan Corp plc: Elan's Prialt meets endpoint in phase III pain trial. Press Release (2004) January 07.
8. Cognetix Inc, Salt Lake City, UT, USA. http://www.cognetix.com
9. Atanassoff PG, Hartnannsgruber MW, Thrasher J, Wemeling D, Longton D, Gaeta R Singh T, Mayo M, McGuire D, Luther RR: Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain. Reg Anesth Pain Med (2000) 25 (3):274-278.
10. Azimi-Zonooz A, Kawa CB, Dowell CD, Olivera BM: Autoradiographic localization of N-type VGCCs in gerbil hippocampus and failure of omega conotoxin MVIIA to attenuate neuronal injury after transient cerebral ischemia. Brain Res (2001) 907 1-2):61-70.
11. Penn RD, Paice JA: Adverse effects associated with the intrathecal administration of ziconotide. Pain (2000) 85 (1-2):291-296.
12. Alexander SP, Mathie A, Peters JA: Guide to receptors and channels, 1st Edition. Br J Pharmacol (2004) 141(Suppl 1):S1-S126.
13. Hille B (Ed): Ion Channels of Excitable Membranes, 3rd Edition. Sinauer Associates Inc, Sunderland, MA, USA (2001).
14. Jan LY, Jan YN: Cloned potassium channels from eukaryotes and prokaryotes. Annu Rev Neurosci (1997) 20:91-123.
15. Karlin A: Emerging structure of the nicotinic acetylcholine receptors. Nat Rev Neurosci (2002) 3 2):102-114.
16. Lindstrom JM: The structure of neuronal nicotinic receptors. In: Handbook of Expenmental Pharmacology, Volume 144. Clementi F, Fomassi D, Gotti C (Eds), Springer-Verlag, Berlin, Germany (2000):101-162.
17. Le Novere N, Corringer PJ, Changeux JP: The diversity of subunit composition in nAChRs: Evolutionary origins, physiologic and pharmacologic consequences. J Neurobiol (2002) 53 (4):447-456.
18. Hogg RC, Bertrand D: Nicotinic acetylcholine receptors as drug targets. Curr Drug Targets CNS Neurol Disord (2004) 3 2):123-130.
19. Carlson NR (Ed): Structure and functions of cells of the nervous system. In: Physiology of Behaviour, 7th Edition. Allyn and Bacon, Boston, MA, USA (2001):26-62.
20. Heading CE: Ziconotide (Elan Pharmaceuticals). IDrugs (2001) 4(3):339-350.
21. AMRAD Corp Ltd: AMRAD fast tracks development of chronic pain drug. Press Release (2002) February 26.
22. 1-adrenoceptor and noradrenaline transporter. Nat Neurosci (2001) 4(9 ):902-907.
23. Alonso D, Khalib Z, Satkunanthanb N, Livett BG: Drugs from the sea: Conotoxins as drug leads for neuropathic pain and other neurological conditions. Mini Rev Med Chem (2003) 3 7):785-787.
24. Metabolic Pharmaceuticals Ltd: Metabolic acquires commercial rights to high potential analgesic compound. Press Release (2003) September 30.
25. Sandall DW, Satkunanathan N, Keays DA, Polidano MA, Liping X, Pham V, Down JG, Khalil Z, Livett BG, Gayler KR: A novel α -conotoxin identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo. Biochemistry (2003) 42(22):6904-6911.
26. Metabolic Pharmaceuticals Ltd: Investor Update. Press Release (2004) September 22.
27. Dave JR, Williams AJ, Moffett JR, Koenig ML, Tortella FC: Studies on neuronal apoptosis in primary forebrain cultures: Neuroprotective/anti-apoptotic action of NR2B NMDA antagonists. Abstr Soc Neurosci (2003) 33:Abs 747.1.
28. Tortella FC, Lu XM, Williams AJ, Cunningham B, Stefanik C, Wagstaff J, Hartings JA: Intrathecal administration of CGX-1007, conantokin-G, reduces infarction and cortical spreading depression in a rat model of focal brain ischemia and reperfusion. Abstr Soc Neurosci (2003) 33:Abs 742.5.
29. Wagstaff JD, Layer RT, Smith LB, Bulaj G, Wei S, Nielsen J, Jones RM, Craig AG, McCabe RT: Glycosylation is critical for the pharmacologic properties of contulakin, a potent, broad-spectrum analgesic conopeptide. Abstr Soc Neurosci (2000) 26:Abs 351.8.
30. Cognetix Inc: Drug development: contulakin-G. Company Communication (2002) August 14.
31. Xenome Ltd: Xenome Patent granted in Europe. Press Release (2003) May 02.
32. Xenome Ltd: Xenome begins phase I pain trials with Xen-2174. Press Release (2004) July 20.
33. Xenome Ltd: Xenome receives $3.2M START grant to develop Chronic Pain Drug with U.S. Expert. Press Release (2003) November 05.